Agenus (AGEN) is higher by 17% this morning. The company announced final results from a single-arm, multi-institutional, open-label, Phase 2 study showing that patients with newly diagnosed glioblastoma multiforme (GBM) who received Agenus' Prophage autologous cancer vaccine added to the standard of care treatment, lived nearly twice as long as expected. In this Phase 2 study, 50% of the patients lived for two years, an encouraging result for a cancer that often kills patients within one year. Prophage patients demonstrated a median overall survival of approximately 24 months and 33% of patients remain alive at 2 years and continue to be followed for survival. In addition to the long-term survival data, vaccine treated patients had a median progression-free survival (PFS) of nearly 18 months, approximately two to three-times longer than patients treated with radiation and temozolomide alone. Importantly, 22% of patients were alive and without progression at 24 months and continue to be followed for survival.
With guidance of maybe the worst CEO in all of biotech, upon comparing apples and apples this company is a big zero and one more failure away from BK. Don't believe me about the poor potential and poor performance.....just go the actual board and see what actual investors think about their results so far and what they are looking for in the future.........it isn't an GPRO board that's for sure. t
You're about 20 cents above the high for the year in a market that has been in a four or five year bull market. So you yourself have been participating because you have the bull, but VICL doesn't have the market. In fact, another CART announcement by another company. AGEN is going to kick VICL's tail in regards to virology, and the biotechs in CART are going to kick VICL's tail there. Keep touting it and the VNN will keep you informed of the truth. t
Come on, this is the day of GOOG.......look it up. The fact that you even ask that question again shows your danger to anyone who would take you seriously as a "vaccine expert" giving out information to the masses. If I were you I would have secretly looked it up and not have ask that question in this forum. VICL, maybe the biggesst nonperformer in this five year bull market, with maybe the biggest danger to become the next APPY. t
The market doesn't' seem to agree with you. In fact, at this time AGEN seems to be doing what you would hope VICL could do. To not even consider this and stay steadfast in that thinking you have would seem to be an honorable thing to do, but in this setting it smacks on arrogance. And the trying to convince people to buy into your "dream" is really dishonorable. But keep pushing it, it is like living by a busy highway, people learn to live with the noise after time, but things won't change and in three years your messages will be exactly the same, VICL if it isn't BK by then will be the same and innovative companies like KITE, and now maybe AGEN will continue to roll along. And if you have real money backing this dog VICL you will be three years older and that much poorer. t
For VICL they have 24 years of only a drug to keep my dog safe from melanoma of the mouth, and not much else to show for it. Moverover, they are falling behind other vaccine based biotechs in the science of better vaccines. They are one more failure away from BK. You don't seem to know too much about the competitors in regards to vaccines, but by your name you seem to think so. VICL is about 17 cents off its low for the year, about 75% lower in value since this recent bull market started about four to five years ago, they have had several big failures, no deals, their competitors have grown in number and prowess, the technology used by others is superior, they have lawsuits in regards to how their CEO handled their last failure, and he was considered last year's worst CEO in the WHOLE biotech space........I don't see how a biotech could do worse, but what is even more stunning is how you can continue to promote it with that background. The problem with business in general, and really biotech in particular is that once you get behind the technology curve it is almost impossible to catch back up and get competitive again. You can keep pushing this trash, but another year of more of the same with VICL not doing anything and you will really look even worse than than you do now........if that is even possible. t
Agenus: Positive P2 HerpV vaccine data is incremental, reiterate Buy on checkpoint inhibitor potential -- MLV & Co. (3.53 -0.04)
MLV & Co. notes, AGEN reported strong efficacy signals from a P2 trial of its HerpV vaccine. This is a positive, as the news renews some confidence in AGEN's cancer vaccine efforts after recent higher profile setbacks in melanoma and lung cancer. That said, with respect to HerpV, firm models it as only a very modest product. Thus, yesterday's +3% move for the stock seems about right. That said, firm reminds investors that current enthusiasm on AGEN is based on its transition to being more exclusively focused on its immune checkpoint modulation program.
VICL is only 17 cents above their low for the year. They are going to get their clock cleaned from AGEN, and all of the newer biotechs using the CART technology. It has an over 50% chance of going BK, and almost 100% chance of going BK if their last ditch flagship drug goes bust based on AGEN's latest data. This is a zero company, but I hope if they do go BK that they are able to sell their melanoma drug to someone so that my dog is safe if he is ever on the beach too long and develops doggy oral melanoma. But I sure hope that drug is able to be kept alive based on how much my dog likes the sun. t
Another misnomer or lie. Dr. Crooke's estate has over 1.2 million shares. A call to their IR would straighten that out. t
People on the VICL board aren't too enthused with VICL and their returns from that company. t
They are in that hot area of CART immunization treatment in CA. Their technology is kind of an off-shoot from some of the others. I believe PFE signed a large agreeement with a small biotech in the same area, though they are kind of behind NVS and others in the area. I'll be trying to learn more about them, but as they are new I don't really have a grasp on their position in the field. I do know that they are way ahead of VICL and their area of work is way ahead of vicl...soon to be always denoted in small letters. t
VICL is only about a few cents above its low for the year. Other immune therapies are really moving up, and VICL is falling farther behind the curve. But my dog is covered in case he gets melanoma......I sleep a lot better at night knowing that even though the CEO was voted the worst in biotech last year. t
VICL is going to have their hands full with all of the immunotherapy biotechs out there. I think they also are antiquated in their technology with the CARt technology and off-shoots coming on I don't think they will be able to compete. I'd take old-time INO over them, and new comer today KITE over them for sure. But there is an invasion of these types of biotechs. I'm still thankful though that if my dog is out on the beach too long and doesn't wear his sunscreen in his mouth that there is a drug out there from VICL to treat his oral melanoma if he should contract it.. Thank you God for VICL. t
This is bordering on professional slander, I think I'd pull back on the useless criticism and if not I would think I'd prepare for some type of legal action. t
The pharm reps will tell you that most patients are on 5mg and 10mg. GS seems to agreed in an increased risk with this drug now in the market place. Time will tell, expect ZAP3 before the end of the year. t
Potential role of Akt signaling in chronic kidney disease
Nephrology Dialysis Transplantation, 06/06/2014 Review Article
Lan A, et al. – The review indicate that renal fibrosis, particularly tubulointerstitial fibrosis, is the common final outcome of almost all chronic kidney diseases. Nonetheless, these data give evidence for a role for Akt in renal fibrosis, but no reviews are available on the role of Akt in the process.
Mr. Jobs, hope you made some money and reconsider your long term strategy. This stock was one of the worst performers over the last six weeks. Going to get worse. Word on the street is that most patients can't break the 5 to 10mg dosage. Liver enzymes are being elevated at higher doses and that doesn't include the diarrhea component. Real life medicine is notably different than a 23 patient highly controlled study. The COMPASS group has a high probability of failing and won't be cost effective as it is trying to accomplish Mission Impossible. GS has extra resources/links that the general investor does not have. Good luck to you though, t
Buy VICL so if your dog develops melanoma of the mouth you might get a discount on the drug treatment. t
What percentage price was VICL up today vs. ISIS??? You usually like to report those kind of things on select days:)) t
Worse yet enjoy your CEO over there at AEGR. I can still remember his fake tears when talking about patients having lethal levels of lipids running throught their arteries........He then shortly went on to raise the price of the drug by another $60K due to "demand???" What a company! t